A Phase 2 interventional study of GSK3228836 and Nucleos(t)ide therapy in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.
Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 16th largest by enrollment, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 3rd registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline
Ages 18+
GlaxoSmithKline
Ages 18–65 · Healthy volunteers
National University Health System, Singapore · Sites in Singapore
Ages 21+
By country, each count listing its studies:
bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 2 · Phase 4 1
First in 2017; this study’s year is marked. 2 started in 2020.
This study's enrollment of 12 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 103 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
144 studies in Hepatitis B by GlaxoSmithKline: 2 open now, 6 under way, none of them phase 3. Of 136 finished, 69 (51%) have results posted.
Among the 144 studies in Hepatitis B by GlaxoSmithKline, this one is the 135th largest by enrollment of the 137 interventional ones that give a count, is one of 2 that started in 2020, is one of 34 in phase 2, and was the 129th registered.
GlaxoSmithKline’s Hepatitis B studies by the year they started, since 1992.
2 of the studies testing bepirovirsen in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905157GlaxoSmithKlineA Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants | 2027-03-30 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing bepirovirsen in Hepatitis B, from their registry updates:
Among GlaxoSmithKline’s 144 in Hepatitis B:
This tab as a report to print or save as PDF → With an account.
Hepatitis B virus (HBV) infection, especially chronic, is a significant worldwide medical problem. This is an exploratory study of the therapeutic mechanism of GSK3228836 in participants with chronic hepatitis B (CHB) on stable nucleos(t)ide therapy (which is the first line therapy for CHB). This study is a Phase IIa, multi-center open label exploratory study of the therapeutic mechanism of GSK3228836 in participants with hepatitis B virus e-antigen (HBeAg)-negative CHB on stable nucleos(t)ide therapy using repeat fine needle aspirations of the liver for intrahepatic immunophenotyping. It will investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine needle aspirates of the liver will be performed to enable analysis of liver-resident immune cells to investigate any immunomodulatory properties of GSK3228836 and to study the biology of underlying treatment-associated liver flares. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately 20 participants will be enrolled in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A male participant is eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study treatment i. Refrain from donating sperm ii. and be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or Must agree to use /barrier as detailed below
1) Agree to use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak) when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant.
A female participant is eligible to participate:
i. If she is not pregnant or breastfeeding. ii. and at least one of the following conditions applies:
<!-- -->
Exclusion Criteria:
Co-infection with:
History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by
Both (AST)- Index (APRI) >2 and FibroSure/FibroTest result >0.7
1) If only one parameter (APRI or FibroSure/FibroTest) result is positive, a discussion with the Medical Monitor is required before inclusion in study is permitted.
Regardless of APRI or Fibrosure/FibroTest score participants will be excluded from the study if their past history includes one of the following criteria:
Diagnosed or suspected hepatocellular carcinoma as evidenced by the following
Anti-neutrophil cytoplasmic antibody (ANCA) at screening by itself won't be an exclusion criterion - but if results are borderline positive or positive:
Low compliment (C)3 at screening or Baseline by itself won't be an exclusion criterion-but if it is present
a. A discussion with the Medical Monitor is required to review participant's complete medical history to ensure no past history or current manifestations of vasculitic/inflammatory/auto-immune conditions.
History of alcohol or drug abuse/dependence
History of or current drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance.
Laboratory results as follows
Total >1.25 times
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on stable nucleos(t)ide therapy will receive GSK3228836 300 mg subcutaneously (SC) weekly once for 12 weeks along with a loading dose of GSK3228836 300 mg in Week 1 (Day 4) and Week 2 (Day 11).
Drug: GSK3228836 · Drug: Nucleos(t)ide therapy
GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleos(t)ide therapy for the duration of the study.
Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ)
Percentage of participants achieving serum HBsAg level \<LLOQ were reported. Percentage values are rounded-off.
Time frame: Up to Week 12
Percentage of Participants With Sustained HBsAg Response (HBsAg <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment
Sustained HBsAg response is defined as HBsAg \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.
Time frame: Up to 24 weeks off treatment (Study Weeks 12 to 36)
Percentage of Participants Achieving Sustained Virologic Response (HBsAg <LLOQ and HBV DNA <LLOQ) for 24 Weeks After the Planned and Actual End of GSK3228836 Treatment
Sustained virologic response is defined as HBsAg \<LLOQ and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.
Time frame: Up to 24 weeks off treatment (Study Weeks 12 to 36)
Percentage of Participants Achieving HBsAg <LLOQ at Indicated Time Points
Percentage of participants achieving HBsAg \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment (OT) Day 162
Percentage of Participants Achieving HBV DNA <LLOQ at Indicated Time Points
Percentage of participants achieving HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Percentage of Participants Achieving HBsAg <LLOQ and HBV DNA <LLOQ at Indicated Time Points
Percentage of participants achieving HBsAg \<LLOQ and HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Percentage of Participants With Categorical Change From Baseline in HBsAg Values at Indicated Time Points
Participants who achieved a decline in HBsAg values from Baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from Baseline values. Percentage values are rounded-off.
Time frame: Baseline (Week -1), Treatment Week 12 and off treatment Week 24
Number of Participants With Alanine Aminotransferase (ALT) Greater Than (>)3 Times Upper Limit of Normal (ULN) at Indicated Time Points
Blood samples were collected at indicated time points to assess ALT levels. The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with Baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
Time frame: Baseline (Week -1), treatment Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162
Number of Participants With HBe Antibody (Anti-HBeAg) Levels
Blood samples were collected to assess HBe antibody levels and results reported are for Baseline HBeAg positive participants.
Time frame: Baseline (Week -1), treatment Days 29, 36, and 57; off treatment Days 1, 8, 22, 50, 78, 106, 134 and 162
Actual Values of HBsAg at Indicated Time Points
Blood samples were collected from participants at indicated time points to assess HBsAg levels.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Mean Change From Baseline in HBsAg at Indicated Time Points
Blood samples were collected from participants at indicated time points to assess HBsAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Actual Values of HBV DNA at Indicated Time Points
Blood samples were collected from participants at indicated time points to assess HBV DNA levels.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Mean Change From Baseline in HBV DNA at Indicated Time Points
Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Week -1), treatment Day 78 and off treatment Day 162
Actual Values of HB Surface Antibody (Anti-HBsAg) Levels at Indicated Time Points
Blood samples were collected from participants at indicated time points to assess anti-HBsAg levels.
Time frame: Baseline (Week -1) and off treatment Days 1 and 162
Area Under the Concentration-time Curve (AUC) for ALT at Indicated Time Points
Blood samples were collected from participants to assess AUC for ALT. On-treatment blood samples were collected from Weeks 1 to 12 and follow-up blood samples were collected from Weeks 12 to 36. AUC was calculated and presented for on-treatment (12 Weeks), follow-up (24 weeks), and On-treatment + follow-up (Weeks 1 to 36).
Time frame: Study Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 20, 24, 28, 32 and 36
Time to Maximum ALT
Time to maximum ALT (maximum peak in ALT) during 36 week (treatment + follow-up) is defined as time from Baseline to the time of first peak in ALT.
Time frame: Up to Study Week 36
This was an open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in participants with Chronic Hepatitis B via intrahepatic immunophenotyping.
| Milestone | GSK3228836 300 mg |
|---|---|
| Started | 12 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of participants achieving serum HBsAg level \<LLOQ were reported. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Percentage of Participants Achieving Serum Hepatitis B Virus Surface Antigen (HBsAg) Level Less Than (<) Lower Limit of Quantitation (LLOQ) | 25 |
Sustained HBsAg response is defined as HBsAg \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Sustained HBsAg Response for 24 Weeks after Planned End of GSK3228836 Treatment | 8 |
| Sustained HBsAg Response for 24 Weeks after Actual End of GSK3228836 Treatment | 8 |
Sustained virologic response is defined as HBsAg \<LLOQ and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<LLOQ for 24 weeks from end of GSK3228836 treatment. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Sustained Virologic Response for 24 Weeks after Planned End of GSK3228836 Treatment | 8 |
| Sustained Virologic Response for 24 Weeks after Actual End of GSK3228836 Treatment | 8 |
Percentage of participants achieving HBsAg \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 0 |
| Treatment Day 78 | 30 |
| Off Treatment Day 162 | 18 |
Percentage of participants achieving HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 92 |
| Treatment Day 78 | 78 |
| Off Treatment Day 162 | 100 |
Percentage of participants achieving HBsAg \<LLOQ and HBV DNA \<LLOQ were assessed at indicated time points. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 0 |
| Treatment Day 78 | 20 |
| Off Treatment Day 162 | 18 |
Participants who achieved a decline in HBsAg values from Baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL). The 'HBsAg \< LLOQ' category is derived based on Absolute/raw HBsAg result. The HBsAg decline categories are based on change from Baseline values. Percentage values are rounded-off.
| Percentage of participants | GSK3228836 300 mg |
|---|---|
| Treatment Week 12, HBsAg < LLOQ | 30 |
| Treatment Week 12, HBsAg decline <0.5 log10 IU/mL | 10 |
| Treatment Week 12, HBsAg decline >=0.5 log10 IU/mL | 90 |
| Treatment Week 12, HBsAg decline >=1 log10 IU/mL | 80 |
| Treatment Week 12, HBsAg decline >=1.5 log10 IU/mL | 80 |
| Treatment Week 12, HBsAg decline >=3 log10 IU/mL | 50 |
| Off Treatment Week 24, HBsAg < LLOQ | 18 |
| Off Treatment Week 24, HBsAg decline <0.5 log10 IU/mL | 73 |
| Off Treatment Week 24, HBsAg decline >=0.5 log10 IU/mL | 27 |
| Off Treatment Week 24, HBsAg decline >=1 log10 IU/mL | 27 |
| Off Treatment Week 24, HBsAg decline >=1.5 log10 IU/mL | 27 |
| Off Treatment Week 24, HBsAg decline >=3 log10 IU/mL | 18 |
Blood samples were collected at indicated time points to assess ALT levels. The ALT normalization (ALT \<=upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with Baseline ALT\>ULN and ALT data at that visit. Participants who achieved ALT normalization were reported.
| Participants | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 0 |
| Treatment Day 8 | 0 |
| Treatment Day 15 | 0 |
| Treatment Day 22 | 0 |
| Treatment Day 29 | 0 |
| Treatment Day 36 | 1 |
| Treatment Day 43 | 1 |
| Treatment Day 50 | 1 |
| Treatment Day 57 | 1 |
| Treatment Day 64 | 1 |
| Treatment Day 71 | 1 |
| Treatment Day 78 | 0 |
| Off Treatment Day 1 | 0 |
| Off Treatment Day 8 | 0 |
| Off Treatment Day 22 | 0 |
| Off Treatment Day 50 | 0 |
| Off Treatment Day 78 | 0 |
| Off Treatment Day 106 | 1 |
| Off Treatment Day 134 | 0 |
| Off Treatment Day 162 | 0 |
Blood samples were collected to assess HBe antibody levels and results reported are for Baseline HBeAg positive participants.
| Participants | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 11 |
| Treatment Day 29 | 11 |
| Treatment Day 36 | 0 |
| Treatment Day 57 | 9 |
| Off Treatment Day 1 | 9 |
| Off Treatment Day 8 | 10 |
| Off Treatment Day 22 | 10 |
| Off Treatment Day 50 | 10 |
| Off Treatment Day 78 | 10 |
| Off Treatment Day 106 | 10 |
| Off Treatment Day 134 | 8 |
| Off Treatment Day 162 | 10 |
Blood samples were collected from participants at indicated time points to assess HBsAg levels.
| Log10 IU/mL | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 3.29 ± 0.590 |
| Treatment Day 78 | 0.33 ± 1.432 |
| Off Treatment Day 162 | 2.08 ± 1.933 |
Blood samples were collected from participants at indicated time points to assess HBsAg levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg |
|---|---|
| Treatment Day 78 | -2.923 ± 1.5803 |
| Off Treatment Day 162 | -1.183 ± 1.8343 |
Blood samples were collected from participants at indicated time points to assess HBV DNA levels.
| Log10 IU/mL | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 0.43 ± 0.849 |
| Treatment Day 78 | 0.31 ± 0.611 |
| Off Treatment Day 162 | 0.24 ± 0.525 |
Blood samples were collected from participants at indicated time points to assess HBV DNA levels. Change from Baseline was defined as value at the indicated time point minus Baseline value. Baseline was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Log10 IU/mL | GSK3228836 300 mg |
|---|---|
| Treatment Day 78 | -0.271 ± 1.1145 |
| Off Treatment Day 162 | -0.237 ± 0.7871 |
Blood samples were collected from participants at indicated time points to assess anti-HBsAg levels.
| Log10 IU/mL | GSK3228836 300 mg |
|---|---|
| Baseline (Week -1) | 0.60 ± 0.000 |
| Off Treatment Day 1 | 0.71 ± 0.238 |
| Off Treatment Day 162 | 0.70 ± 0.260 |
Blood samples were collected from participants to assess AUC for ALT. On-treatment blood samples were collected from Weeks 1 to 12 and follow-up blood samples were collected from Weeks 12 to 36. AUC was calculated and presented for on-treatment (12 Weeks), follow-up (24 weeks), and On-treatment + follow-up (Weeks 1 to 36).
| Weeks*International Units Per Liter | GSK3228836 300 mg |
|---|---|
| On-Treatment (12 Weeks) | 494.75 ± 562.593 |
| Follow-up (24 weeks) | 650.58 ± 462.762 |
| On-Treatment + Follow-Up (Weeks 1 to 36) | 1173.72 ± 836.768 |
Time to maximum ALT (maximum peak in ALT) during 36 week (treatment + follow-up) is defined as time from Baseline to the time of first peak in ALT.
| Weeks | GSK3228836 300 mg |
|---|---|
| Time to Maximum ALT | NA (27.1 to NA) |
Collected over Up to Study Week 36. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK3228836 300 mg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| Event | GSK3228836 300 mg |
|---|---|
| Injection site erythemaGeneral disorders | 7/12 |
| Injection site pruritusGeneral disorders | 4/12 |
| Procedural painInjury, poisoning and procedural complications | 3/12 |
| FatigueGeneral disorders | 2/12 |
| Injection site bruisingGeneral disorders | 2/12 |
| Injection site painGeneral disorders | 2/12 |
| PyrexiaGeneral disorders | 2/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 |
| DizzinessNervous system disorders | 2/12 |
| HeadacheNervous system disorders | 2/12 |
| Age, Continuous(Years) | GSK3228836 300 mg |
|---|---|
| Mean | 48.8 ± 8.48 |
| Sex/Gender, Customized(Participants) | GSK3228836 300 mg |
|---|---|
| De-identified | 12 |
| Race/Ethnicity, Customized(Participants) | GSK3228836 300 mg |
|---|---|
| De-identified | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Oct 2020 to primary completion in Nov 2023, 37 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's 37 months is above that.
Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bepirovirsen